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Objective: To determine if tyrosine kinase receptor inhibitor, sunitinib malate, combined with chemo-
therapeutic drugs may present synergistic enhancement of cytotoxicity to transitional cell carcinoma
cells (TCC).
Methods: The mRNA and protein contents of vascular endothelial growth factor-a (VEGFa) in various TCC
cell lines were detected individually by quantitative-polymerase chain reaction and Western blot. The
inhibitory concentrations of various chemotherapeutic drugs, including gemcitabine, doxorubicin, and
cisplatin, and their combination with sunitinib to TCC cancer cells were determined by 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The synergist efﬁcacy was measured
using the observed/expected ratio calculation method. Finally, the synergistic effect of sunitinib and
selected anticancer drug gemcitabine was elucidated in C3H/MBT-2 animal tumor model with moni-
toring tumor growth volume and survival rate.
Results: The mRNA of VEGFa had high expression in high-grade TCC cell lines (T24, TCC 8701, and TCC
8702) when compared with low-grade TCC cell lines (TCC 8301 and TSGH 9201). The expression of
VEGFa protein level was closely correlated with the mRNA content in each individual cell line. Sunitinib,
combined with gemcitabine, has shown the highest synergistic cytotoxic effect to TCC cells in an MTT
assay. In the xenografted tumor model, MBT-2 bearing mice treated by sunitinib and gemcitabine
combination had the lower mean tumor volume (265  95 mm3 vs. 2605  320 mm3) and higher
survival rate (100% vs. 56%) at 30 days follow-up when compared with control mice.
Conclusion: Combination of the tyrosine kinase receptor inhibitor sunitinib with gemcitabine chemo-
therapy synergistically enhances tumor cytotoxicity and may provide a new treatment modality for
advanced bladder cancer.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
In Taiwan, the incidence of urothelial carcinomas is increasing
yearly. A total of 735 victims died of bladder cancer in 2010 with a
standard mortality rate of 2.2/100,000 according to the statistics
from the Department of Health, Executive Yuan, Taiwan, R.O.C.1 In
patients with urothelial carcinoma, around 90% have transitional
cell carcinoma (TCC). Of these, 15e20% will invade into the outer
tissues of bladder or the pelvic lymph nodes with distant metas-
tasis.2 Therefore, high recurrence with disease progression is a
clinical characteristic of bladder cancer. Currently, the available
treatment for advanced and metastatic bladder cancer is systemicervice General Hospital, Na-
g-Gung Road, Nei-Hu, Taipei
ciation. Published by Elsevier Taiwchemotherapy. Although randomized trials have established an
incremental beneﬁt from the addition of chemotherapy in this
setting, many patients still have disease relapse, and therefore it is
necessary to investigate more efﬁcient treatment modalities for
this disease entity.
Large efforts have been devoted to the development of new
chemotherapeutic reagents and the design of new strategies for
prevention recurrence and metastatic bladder cancers. Primary
bladder tumors and metastatic sites appear to be highly vascular.
The critical role of angiogenesis in tumor growth and metastasis
has prompted many efforts to develop antiangiogenic therapies,
thus providing a rational drug target for using angiogenic inhibitors
in bladder cancer tumors.3 Sunitinib malate is one of several new
antiangiogenic agents undergoing tests of efﬁcacy in the treatment
of various types of cancer, including gastrointestinal stromal tu-
mors and renal cell carcinoma.4 This study attempts to verify the
possible synergistic effect of anticancer drugs and sunitinib in
treating TCC.an LLC. Open access under CC BY-NC-ND license.
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Human TCC cell lines (high-grade: T24, TCC8701 and TCC8702;
low-grade: TSGH8301 and TSGH9201) and a mouse bladder cancer
cell line (MBT-2; JCRB, Tokyo, Japan), were cultivated in an Roswell
Park Memorial Institute (RPMI)-1640 medium supplemented with
10% fetal bovine serum (Copenhagen, DK), with 100 U/mL peni-
cillin, 50 mg/mL streptomycin, nonessential amino acid, and 0.01M
4-(2-hydroxyethyl)-1- piperazine ethanesulfonic acid (HyClone,
DK). Conﬂuent cells were detached with 0.01M EDTA.
Sunitinib malate (Sutent) was generously provided by Pﬁzer Inc.
(City, Taiwan). Twenty-ﬁve mg of sunitinib was dissolved in 5 mL of
phosphate buffered saline (PBS) (pH 6.5) to make 5 mg/mL stock.
Gemcitabine and doxorubicin were generously provided by TTY
Biopharm (City, Taiwan). Cisplatin was purchased from Sigma-
Aldrich (St Louis, MO, USA).
Quantitative polymerase chain reaction (qPCR) detection of
vascular endothelial growth factor-a (VEGFa) mRNA was conducted
by a three-step procedure using the ABI 7500 instrument (ABI, Foster
City, CA, USA). First, mRNA was extracted from cell lysate. Second,
cDNA was synthesized with a Moloney murine leukemia virus high
performance reverse transcriptase kit (Epicentre Biotechnologies,
Madison, WI, USA) using 1 mg of RNA and 0.2 mg oligo-dT serving as
primers in a total volume of 20 mL and diluted to 1/100 fold. Third,
4.5mLof thecDNAwasampliﬁedusing9mLof theSmartQuantGreen
MasterMixwithdUTPandROX(Protech, Birmingham,UK)and0.9mL
ofmixedprimersand3.6mLQ-H2O.During theqPCR, a 125basepairs
fragment of VEGFa-encoding mRNA was ampliﬁed from the cDNA.
The ampliconwas detected bymeans of ﬂuorescence, using a speciﬁc
pair of VEGF-a primers: forward primer 50- CTTGTTCAGAGCGGAG
AAAGC-30 and reverse primer 50-ACATCTGCAAGTACGTTCGTT-30. The
ﬂuorescence emitted after hybridization to the template DNA was
measured. In a separate qPCR, mRNA encoding for hypoxanthine-
guanine phosphoribosyl transferase primers: forward primer 50-GT
TAAGCAGTACAGCCCCAAA-30 and reverse primer 50-AGGGCATA
TCCAACAACAAACTT-30 was processed as a housekeeping gene. Its
product servedasa control forRNAandrelativequantiﬁcation.All PCR
reactions were performedwith hot start activatedwith 15minutes at
95C, 40 cycles of 15 seconds at 95C, 30 seconds at 60C, and 35
seconds at 72C, and 2 minutes at 72C.
For VEGFa protein detection, 106 exponentially growing various
TCC cells were cultured as usual and treated for 24 hours. They
were then pelleted by centrifugation, washed with PBS twice, and
resuspended in 1 mL of PBS solution. A 100 mL aliquot of immu-
noﬂuorescence conjugated mouse antibody raised to VEGFa
(1:1000 diluted, Millipore Comp., Billerica, MA, USA) was added
and cultured in room temperature for 30 minutes. After being
washed with PBS twice, analysis was performed on the
ﬂuorescence-activated cell sorting Calibur using CellQuest (BD
FACSCalibur, CellQuest Inc., Largo, FL).
In the cytotoxic assay, representative low-grade and high-
grade TCC cell lines, TSGH8301 and T24, were exposed to
chemotherapeutic drugs. These included doxorubicin, gemcita-
bine, and cisplatin combined with various concentrations of
sunitinib for 48 hours. Cellular viability was detected using a
modiﬁed 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide (MTT) assay. In brief, MBT-2 cells (2000 per well)
in 100 mL culture medium were seeded into 96-well microplates
and incubated at 37 C for 12 hours prior to drug exposure. The
plated cell numbers were calculated to keep control cells
growing in the exponential phase throughout the 48-hour in-
cubation period. For concurrent treatment, cells were treated
with both single chemotherapeutic drugs and sunitinib (each in
100 mL of culture medium) simultaneously and incubated for 48
hours. Then 50 mL of MTT (2 mg/mL in RPMI medium) wereadded to each well and allowed to react for 3 hours. The blue
formazan crystals formed were pelleted to the well bottoms by
centrifugation, separated from the supernatant, and dissolved in
100 mL of dimethyl sulfoxide. The optical density was determined
by absorbance spectrometry at 560 nm using an enzyme-linked
immunosorbent assay reader (Multiskan ex; Thermo Fisher,
Waltham, MA, USA). Three separate experiments with triplicate
runs in each were performed to obtain mean cell viability. The
drug concentrations inhibiting cell growth by 50% (IC50) were
determined using Calcusyn1 (Version 1.1.1, 1996; Biosoft Inc.,
Cambridge, UK).5
The combined effects of the chemotherapeutic drug and suni-
tinib were subjected to an observed and expected ratio. Control
experiments replaced the active agent with a drug-free medium. By
combining two agents at graded concentrations, numerous com-
bined effects of growth inhibition were obtained and analyzed
using observed/expected (O/ E) ratio. A statistical functionwas used
for analysis:
fðuÞA;B ¼ fðuÞAþ fðuÞB
where f(u)A ¼ the fraction unaffected by drug A, f(u)B ¼ the frac-
tion unaffected by drug B, and f(u)A, B ¼ the fraction unaffected by
drugs A and B and formula:
ðA drug and B drug combination survival rateÞ=½
 ðA drug survival rateÞ þ ðB drug survival rateÞ
O/E ratios < 1, 1e2, and >2 indicate synergism, additivism, and
antagonism, respectively. The expected (presumed to be additive or
synergistic) and observed survival rates of TCC cells were obtained
from three independent drug-combined treatments.6
In the animal study, C3H mice (8 weeks old, n ¼ 10 in each
group) were obtained from the breeding colony of the National
Laboratory Animal Center. Prior to initiating the experiment, we
acclimatized all mice to a pulverized diet for 3 days. Our experi-
mental protocol was reviewed and approved by the National De-
fense Medical Center Laboratory Animal Center. MBT-2 cells
(1  106) in 100 mL PBS were injected into the subcutaneous ﬂank
region using a 27-gauge needle. Visible growing tumors established
themselves within 2 weeks after inoculation. Gemcitabine (3.8 mg/
mL  8 shots) was injected intraperitoneally twice a week. Suni-
tinib (0.25 mg/day) was given daily through oral tube feeding in a 3
weeks on and 1 week off regimen similar to clinical usage. The
cotreatment group of sunitinib and gemcitabine complied with the
same regimen. The day of cell implantation was designated Day 0.
The tumors of the treated group and control group were measured
daily with vernier calipers in order to measure the long and short
dimensions. Body weight was assessed daily after cell injection.
After 30 days, the animals were euthanized and the primary tumors
in their ﬂanks were excised, weighed, and processed for histo-
pathological examination.
The expression of mRNA, cytotoxicity in MTT assay, and xeno-
grafted tumor volume were expressed as mean  standard devia-
tion. TheManneWhitney U test was used for statistical comparison
with differences considered signiﬁcant at p < 0.05.3. Results
Real-time PCR assay of VEGFa mRNA in various TCC cell lines
As shown in Fig.1, high-grade TCC cell lines (T24, TCC8701, andTCC
8702) have higher content of VEGFa mRNA than low-grade TCC cell
lines (TCC 8301 and TCC 9201) with 3e6 fold increased changes
(p < 0.01).
Fig. 1. Expression of vascular endothelial growth factor-a mRNA in transitional cell
carcinoma cell lines measured by reverse transcription polymerase chain reaction.
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The mean ﬂuorescence of VEGFa protein expression measured
by ﬂow cytometry is shown in Fig. 2. The measurement reveals that
the expression of VEGFa protein is also parallel correlated with
mRNA content in measured the TCC cell lines. VEGFa protein
expressionwasmarked as having increasedmore in high-grade TCC
cell lines (T24, TCC8701 and TCC 8702) than in low-grade TCC cell
lines (TCC 8301 and TCC 9201; p< 0.05). The MBT-2 mouse TCC cell
line has moderate expression of VEGFa protein (data not shown).
MTT assay of chemotherapeutic drug and sunitinib combinations on
TCC cell lines and calculated paired drug combination indexes
As shown in Table 1, individual doxorubicin had the highest
cytotoxicity to low grade TCC-TSGH8301, whereas individual
gemcitabine had the highest cytotoxicity to high-grade TCC-T24 in
the IC50 comparison. Both TCC cell lines were moderately sensitive
to sunitinib treatment with lower IC50 in high-grade TCC-T24 than
low-grade TCC-TSGH8301. Interestingly, among these paired drug
combinations, sunitinib combined with gemcitabine presented
with the highest synergistic cytotoxicity to TCC cells, either
TSGH8301 or T24, with O/E ratio < 1.
Animal tumor growth inhibition in sunitinib and gemcitabine
combination therapy
The conﬁrmatory experiment revealed that sunitinib and gem-
citabine alone has signiﬁcant tumor inhibition effect at 30 days
after drug treatment when compared to control mice
(1450  280 mm3 and 1030  110 mm3 vs. 2605  320 mm3,
p ¼ 0.04; Fig. 3). Accordingly, the use of sunitinib plus gemcitabine
demonstrated the most effective tumor inhibition than the control
mice (265  95 mm3 vs. 2,605  320 mm3, p ¼ 0.01). No toxic ef-
fects from the therapy were observed in the three animal groups.
All mice in the gemcitabine and sunitinib with gemcitabine
combination treatment groups survived at 30 days, compared to 56%
of the control group and 86% of the sunitinib group (p¼ 0.02; Fig. 4).
4. Discussion
In a variety of different solid tumors, high expression of VEGFa is
associated with increased microvessel density in tumor tissues,
disease progression, and metastasis.7,8 VEGFa regulates endothelial
cell proliferation, differentiation, and survival via interactions withVEGFa receptors in tumor cell membranes. Animal models, as well
as clinical studies, have identiﬁed elevated levels of various cyto-
kines and growth factors during tumor progression and metastatic
spread, including basic ﬁbroblast growth factor, interleukin-8,
hypoxia-inducible factor, and VEGFa.9e16 The critical role of
angiogenesis in tumor growth and metastasis has prompted major
efforts to develop antiangiogenic therapies.
It is known that chemotherapy regimens, combined with anti-
angiogenic drugs can induce remarkable cytotoxic responses.17
Although angiogenesis-dependent growth has been documented
for several tumor types, conﬂicting data are availablewith respect to
bladder TCC. Signiﬁcant differences in VEGFa serum level were
observed inhealthy controls andpatientswith bladder cancer,which
was closely associated with tumor stage, grade, vascular invasion,
and carcinoma in situ.18 Another study has demonstrated the asso-
ciation of preoperative urinary VEGFa levelswith a risk of recurrence
in patients with superﬁcial bladder TCC, although there was no sta-
tistical correlation between VEGFa levels and tumor stage, tumor
size, or tumor grade.19 The mechanisms by which EGFR signaling
pathways regulate VEGFa, interleukin-8, and basic ﬁbroblast growth
factor are unclear, but it is established that upregulation of these
factors follows activation of the epidermal growth factor receptor
signaling pathways by epidermal growth factor or transforming
growth factor-a. However, a relationship of VEGFa with disease
progression in patients with superﬁcial bladder tumors is not yet
accepted.20 In addition to the currently used bacillus Calmettee
Guerin and anticancer drugs for prophylactic treatment and therapy
of superﬁcial bladder cancer, a rational development for using
intravesical therapy to target the recurrence of neovascularization in
order to achieve constant and durable results must be tested.
The aim of this study was to identify the most effective com-
bination of chemotherapeutic agents with sunitinib for bladder
cancer treatment. From an in vitroMTTassay, gemcitabine has been
selected as the ﬁrst choice for a combination trial with sunitinib to
decrease the side effects of chemotherapeutics. Gemcitabine is a
nucleoside analog with interference on DNA replication and
apoptosis induction of cancer cells. Gemcitabine became a ﬁrst-line
treatment for invasive bladder cancer with metastases in combi-
nation with cisplatin after a study in 2000 with 405 patients
showed similar efﬁcacy, but less toxicity, when compared to the
former methotrexate, vinblastine, adriamycin, and cisplatin
(MVAC) regimen.21 To date, sunitinib and sorafenib have been
demonstrated to improve the progression-free survival in patients
with metastatic renal cell carcinoma.22 Silay and Miroglu23 sug-
gested that, theoretically, these two new agents may also increase
the progression-free survival of the patients with advanced bladder
carcinoma, because of their antiangiogenic and tumor cell
apoptotic effects. Bradley et al24 conducted anti-VEGFa receptor
monotherapy Phase II trial therapy using sunitinib in advanced
bladder cancer patients after chemotherapy. Dreicer et al25 re-
ported that using sorafenib as a single agent has minimal activity in
patients with advanced urothelial cancer in the second-line setting.
Sridhar et al26 reported that sorafenib does not show sufﬁcient
activity as a single agent in ﬁrst-line metastatic urothelial cancer.
Gallagher et al27 reported that sunitinib treatment had not reached
the predetermined therapeutic threshold in metastatic urothelial
cancer patients, but they did observe antitumor responses.
Recently Vogelzang28 reported one patient of bladder cancer with
lung metastases treated by sunitinib and gemcitabine effectively
with a stable condition. However, no consistent evidence supports
the idea that the usage of sunitinib as monotherapy of combination
for invasive bladder cancer is effective.
It has previously been shown that VEGFa is abnormally
expressed in TCC and that it promotes cancer malignancy.29 In our
study, it is interesting to ﬁnd that the VEGFa content was in
Table 1
MTT cytotoxic assay of chemotherapeutic drugs and sunitinib on TCC cell lines,
TSGH8301 (low grade) and T24 (high grade), and calculated observed/expected ratio
(combination index, CI) of paired drug combinations.
TSGH8301 T24
Paired drugs IC50  SD (mM) CIa IC50  SD (mM) CI
Sunitinib 7.25  0.28 0.51 4.21  0.26 0.32
Cisplatin 6.78  0.31 3.12  0.14
Sunitinib 7.21  0.12 0.48 3.85  0.18 0.62
Doxorubicin 0.19  0.25 1.44  0.22
Sunitinib 6.92  0.27 0.25 4.03  0.08 0.14
Gemcitabine 1.96  0.17 13.13  0.11
IC 50 ¼ drug concentration inhibiting cell growth by 50%; SD ¼ standard deviation.
a CI >1, antagonistic effect; CI ¼ 1, additive effect; CI <1, synergistic.
Fig. 2. Expression of vascular endothelial growth factor-a protein measured by immunoﬂuorescence ﬂow cytometry in high-grade transitional cell carcinoma cell lines, (A) T24, (B)
TCC8701, and (C) TCC 8702, and low-grade transitional cell carcinoma cell lines, (D) TCC 8301 and (E) TCC 9201.
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expression was seen in high-grade TCC cells. This indicates that
TKI inhibitors, such as sunitinib, may conduct an anticancer effect
in facing high-grade TCC tumors. The speciﬁc hypothesis of this
study is that sunitinib, in conjunction with an anticancer drug,
will decrease the tumor volume of the bladder or metastases and
prolong tumor-carrying host survival. Our rationale is that suni-
tinib may synergistically enhance the cytotoxicity of anticancer
drugs to TCC cells through its VEGFa inhibition effect. Further-
more, as shown in our previous study, when operating to coun-
teract VEGFa activity, sunitinib also seems to be able to increase
the apoptotic pathway of tumor cells with increased intracellular
bcl proteins.30 Yoon et al31 reported that sunitinib malate has a
potent antitumor effect and may synergistically enhance the
antitumor effect of gemcitabine in human bladder cancer cell
Fig. 3. C3H/MBT-2 xenografted tumor growth treated by sunitinib, gemcitabine and their combination. (A) The ﬁnal mean volume of tumors at 30 days after serial treatment. (B)
Representative gross and (C) microscopic (hematoxylin and eosin stain,  200) pictures of subcutaneous tumor in C3H mice.
D.-S. Yu / Urological Science 25 (2014) 48e5352lines. In this study we have reconﬁrmed the similar therapeutic
effects of a sunitinib and gemcitabine combination for bladder
cancer from both in vitro and in vivo aspects.
In conclusion, our study demonstrated that sunitinib has direct
anticancer efﬁcacy to TCC cells and can synergistically enhance the
gemcitabine cytotoxicity with inhibition of tumor growth, and that
this protocol can prolong survival of xenografted animals with
bladder cancer. This regimen may have potential therapeutic
application in the future as an alternative treatment for clinical
patients with invasive bladder cancer.Fig. 4. Consequent survival curves of four groups of C3H/MBT2 tumor bearing mice
treated by sunitinib, gemcitabine, and their combinations.Conﬂicts of interest
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